X
ROIV icon

Xponance’s Roivant Sciences ROIV Stock Holding History

Xponance’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
62,351
+7,681
+14% +$227K 0.01% 563
2026
Q1 		$1.51M Buy
54,670
+14,870
+37% +$382K 0.01% 625
2025
Q4 		$864K Sell
39,800
-6,918
-15% -$136K 0.01% 734
2025
Q3 		$707K Buy
46,718
+882
+2% +$10.9K 0.01% 833
2025
Q2 		$517K Sell
45,836
-3,428
-7% -$37.2K ﹤0.01% 937
2025
Q1 		$497K Sell
49,264
-55
-0.1% -$595 ﹤0.01% 929
2024
Q4 		$583K Buy
49,319
+2,607
+6% +$30.8K 0.01% 907
2024
Q3 		$539K Buy
46,712
+9,740
+26% +$111K 0.01% 914
2024
Q2 		$391K Sell
36,972
-34,328
-48% -$376K ﹤0.01% 979
2024
Q1 		$752K Buy
71,300
+25,415
+55% +$274K 0.01% 808
2023
Q4 		$515K Sell
45,885
-919
-2% -$8.96K 0.01% 922
2023
Q3 		$547K Buy
46,804
+13,291
+40% +$150K 0.01% 855
2023
Q2 		$338K Buy
+33,513
New +$300K ﹤0.01% 1020

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Xponance's ROIV Position: Q2 2026 in Review

Xponance increased its Roivant Sciences (ROIV) stake by 14% in Q2 2026, buying an estimated $227K and bringing the position to 62,351 shares worth $2.21M. The position accounts for 0.01% of the portfolio, ranked #563.

Xponance first reported a position in ROIV in Q2 2023 and has held it in 13 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Xponance held 62,351 shares of Roivant Sciences worth $2.21M as of Q2 2026.
  • Xponance bought 7,681 Roivant Sciences shares in Q2 2026, an estimated $227K.
  • Roivant Sciences made up 0.01% of Xponance's portfolio in Q2 2026, its #563 holding.
  • Xponance first reported a position in Roivant Sciences in Q2 2023 and has held it in 13 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.